Annual CFI
$153.53 M
+$94.25 M+158.97%
31 December 2023
Summary:
Sangamo Therapeutics annual cash flow from investing activities is currently $153.53 million, with the most recent change of +$94.25 million (+158.97%) on 31 December 2023. During the last 3 years, it has risen by +$425.16 million (+156.52%). SGMO annual CFI is now -38.14% below its all-time high of $248.20 million, reached on 31 December 2021.SGMO Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
$233.00 K
+$106.00 K+83.46%
30 September 2024
Summary:
Sangamo Therapeutics quarterly cash flow from investing activities is currently $233.00 thousand, with the most recent change of +$106.00 thousand (+83.46%) on 30 September 2024. Over the past year, it has dropped by -$37.39 million (-99.38%). SGMO quarterly CFI is now -99.74% below its all-time high of $89.30 million, reached on 30 June 2021.SGMO Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$73.91 M
-$37.39 M-33.60%
30 September 2024
Summary:
Sangamo Therapeutics TTM cash flow from investing activities is currently $73.91 million, with the most recent change of -$37.39 million (-33.60%) on 30 September 2024. Over the past year, it has dropped by -$84.53 million (-53.35%). SGMO TTM CFI is now -70.22% below its all-time high of $248.20 million, reached on 31 December 2021.SGMO TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SGMO Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +159.0% | -99.4% | -53.4% |
| 3 y3 years | +156.5% | -99.6% | +13.5% |
| 5 y5 years | +186.2% | +101.4% | +280.3% |
SGMO Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -38.1% | +156.5% | -99.6% | +101.7% | -70.2% | +24.7% |
| 5 y | 5 years | -38.1% | +156.5% | -99.7% | +100.1% | -70.2% | +127.2% |
| alltime | all time | -38.1% | +156.5% | -99.7% | +100.1% | -70.2% | +122.9% |
Sangamo Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $233.00 K(+83.5%) | $73.91 M(-33.6%) |
| June 2024 | - | $127.00 K(-99.6%) | $111.30 M(-27.6%) |
| Mar 2024 | - | $35.84 M(-5.0%) | $153.64 M(+0.1%) |
| Dec 2023 | $153.53 M(+159.0%) | $37.71 M(+0.2%) | $153.53 M(-3.1%) |
| Sept 2023 | - | $37.63 M(-11.4%) | $158.44 M(+47.6%) |
| June 2023 | - | $42.47 M(+18.9%) | $107.35 M(+15.0%) |
| Mar 2023 | - | $35.73 M(-16.2%) | $93.31 M(+57.4%) |
| Dec 2022 | $59.28 M(-76.1%) | $42.61 M(-416.5%) | $59.28 M(-14.5%) |
| Sept 2022 | - | -$13.46 M(-147.4%) | $69.31 M(-51.8%) |
| June 2022 | - | $28.43 M(+1567.4%) | $143.75 M(-29.7%) |
| Mar 2022 | - | $1.71 M(-96.8%) | $204.62 M(-17.6%) |
| Dec 2021 | $248.20 M(-191.4%) | $52.63 M(-13.7%) | $248.20 M(+281.2%) |
| Sept 2021 | - | $60.98 M(-31.7%) | $65.11 M(-127.3%) |
| June 2021 | - | $89.30 M(+97.2%) | -$238.37 M(-4.7%) |
| Mar 2021 | - | $45.29 M(-134.7%) | -$250.06 M(-7.9%) |
| Dec 2020 | -$271.63 M(+354.2%) | -$130.46 M(-46.2%) | -$271.63 M(+72.4%) |
| Sept 2020 | - | -$242.50 M(-412.5%) | -$157.57 M(-329.3%) |
| June 2020 | - | $77.61 M(+227.2%) | $68.71 M(-422.9%) |
| Mar 2020 | - | $23.72 M(-244.6%) | -$21.28 M(-64.4%) |
| Dec 2019 | -$59.80 M(-66.4%) | -$16.40 M(+1.1%) | -$59.80 M(-407.7%) |
| Sept 2019 | - | -$16.22 M(+31.0%) | $19.44 M(-83.6%) |
| June 2019 | - | -$12.38 M(-16.3%) | $118.42 M(-165.3%) |
| Mar 2019 | - | -$14.80 M(-123.6%) | -$181.34 M(+1.8%) |
| Dec 2018 | -$178.11 M(+130.1%) | $62.84 M(-24.1%) | -$178.11 M(-16.4%) |
| Sept 2018 | - | $82.77 M(-126.5%) | -$212.97 M(-34.0%) |
| June 2018 | - | -$312.14 M(+2598.6%) | -$322.80 M(+239.7%) |
| Mar 2018 | - | -$11.57 M(-141.4%) | -$95.03 M(+22.8%) |
| Dec 2017 | -$77.40 M(-527.1%) | $27.97 M(-203.4%) | -$77.40 M(-21.9%) |
| Sept 2017 | - | -$27.06 M(-67.9%) | -$99.11 M(+147.6%) |
| June 2017 | - | -$84.37 M(-1492.5%) | -$40.03 M(-198.9%) |
| Mar 2017 | - | $6.06 M(-3.3%) | $40.48 M(+123.3%) |
| Dec 2016 | $18.13 M(-76.6%) | $6.27 M(-80.4%) | $18.13 M(-68.3%) |
| Sept 2016 | - | $32.02 M(-929.3%) | $57.10 M(+21.4%) |
| June 2016 | - | -$3.86 M(-76.3%) | $47.05 M(+10.1%) |
| Mar 2016 | - | -$16.30 M(-136.0%) | $42.72 M(-44.9%) |
| Dec 2015 | $77.46 M(-177.0%) | $45.24 M(+106.0%) | $77.46 M(+142.8%) |
| Sept 2015 | - | $21.96 M(-368.2%) | $31.90 M(-143.4%) |
| June 2015 | - | -$8.19 M(-144.4%) | -$73.54 M(-14.6%) |
| Mar 2015 | - | $18.45 M(-5883.1%) | -$86.10 M(-14.5%) |
| Dec 2014 | -$100.66 M(+47.8%) | -$319.00 K(-99.6%) | -$100.66 M(-40.5%) |
| Sept 2014 | - | -$83.47 M(+302.3%) | -$169.28 M(+100.3%) |
| June 2014 | - | -$20.75 M(-633.9%) | -$84.53 M(+39.7%) |
| Mar 2014 | - | $3.89 M(-105.6%) | -$60.50 M(-11.2%) |
| Dec 2013 | -$68.12 M(-701.8%) | -$68.95 M(-5482.2%) | -$68.12 M(-959.5%) |
| Sept 2013 | - | $1.28 M(-60.9%) | $7.92 M(+21.7%) |
| June 2013 | - | $3.28 M(-187.9%) | $6.51 M(+129.4%) |
| Mar 2013 | - | -$3.73 M(-152.6%) | $2.84 M(-74.9%) |
| Dec 2012 | $11.32 M | $7.10 M(-5559.2%) | $11.32 M(-1367.5%) |
| Sept 2012 | - | -$130.00 K(-67.3%) | -$893.00 K(-104.7%) |
| June 2012 | - | -$397.00 K(-108.4%) | $18.88 M(-184.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2012 | - | $4.75 M(-192.8%) | -$22.46 M(+12.3%) |
| Dec 2011 | -$20.00 M(-261.6%) | -$5.12 M(-126.0%) | -$20.00 M(+80.2%) |
| Sept 2011 | - | $19.64 M(-147.1%) | -$11.10 M(-61.1%) |
| June 2011 | - | -$41.73 M(-679.1%) | -$28.54 M(-236.6%) |
| Mar 2011 | - | $7.21 M(+90.2%) | $20.89 M(+68.8%) |
| Dec 2010 | $12.37 M(-164.5%) | $3.79 M(+72.8%) | $12.37 M(-156.2%) |
| Sept 2010 | - | $2.19 M(-71.6%) | -$22.03 M(+7.3%) |
| June 2010 | - | $7.71 M(-687.7%) | -$20.54 M(-10.2%) |
| Mar 2010 | - | -$1.31 M(-95.7%) | -$22.86 M(+19.2%) |
| Dec 2009 | -$19.18 M(-180.6%) | -$30.61 M(-931.5%) | -$19.18 M(-214.1%) |
| Sept 2009 | - | $3.68 M(-31.6%) | $16.80 M(-6.8%) |
| June 2009 | - | $5.38 M(+127.0%) | $18.02 M(-12.4%) |
| Mar 2009 | - | $2.37 M(-55.8%) | $20.58 M(-13.5%) |
| Dec 2008 | $23.79 M(-189.3%) | $5.37 M(+9.4%) | $23.79 M(+41.7%) |
| Sept 2008 | - | $4.91 M(-38.2%) | $16.79 M(-184.7%) |
| June 2008 | - | $7.94 M(+42.2%) | -$19.83 M(-19.7%) |
| Mar 2008 | - | $5.58 M(-441.6%) | -$24.68 M(-7.4%) |
| Dec 2007 | -$26.64 M(+117.8%) | -$1.63 M(-94.8%) | -$26.64 M(+5.8%) |
| Sept 2007 | - | -$31.71 M(-1127.6%) | -$25.18 M(+596.8%) |
| June 2007 | - | $3.09 M(-14.8%) | -$3.61 M(-53.2%) |
| Mar 2007 | - | $3.62 M(-2112.2%) | -$7.72 M(-36.9%) |
| Dec 2006 | -$12.23 M(+176.2%) | -$180.00 K(-98.2%) | -$12.23 M(-55.7%) |
| Sept 2006 | - | -$10.14 M(+890.4%) | -$27.64 M(+120.7%) |
| June 2006 | - | -$1.02 M(+15.6%) | -$12.52 M(+64.4%) |
| Mar 2006 | - | -$886.00 K(-94.3%) | -$7.62 M(+72.0%) |
| Dec 2005 | -$4.43 M(-152.5%) | -$15.59 M(-413.4%) | -$4.43 M(-129.9%) |
| Sept 2005 | - | $4.97 M(+28.1%) | $14.80 M(+24.5%) |
| June 2005 | - | $3.88 M(+68.6%) | $11.89 M(+30.9%) |
| Mar 2005 | - | $2.30 M(-36.7%) | $9.08 M(+7.7%) |
| Dec 2004 | $8.43 M(-1453.8%) | $3.64 M(+76.5%) | $8.43 M(+107.2%) |
| Sept 2004 | - | $2.06 M(+91.3%) | $4.07 M(-18.8%) |
| June 2004 | - | $1.08 M(-34.9%) | $5.02 M(+52.3%) |
| Mar 2004 | - | $1.66 M(-328.6%) | $3.29 M(-628.6%) |
| Dec 2003 | -$623.00 K(-103.3%) | -$724.00 K(-124.1%) | -$623.00 K(-135.3%) |
| Sept 2003 | - | $3.01 M(-566.2%) | $1.76 M(-111.1%) |
| June 2003 | - | -$645.00 K(-71.5%) | -$15.83 M(+52.9%) |
| Mar 2003 | - | -$2.26 M(-236.0%) | -$10.35 M(-154.9%) |
| Dec 2002 | $18.88 M(+576.3%) | $1.66 M(-111.4%) | $18.88 M(+276.1%) |
| Sept 2002 | - | -$14.59 M(-402.0%) | $5.02 M(-81.0%) |
| June 2002 | - | $4.83 M(-82.1%) | $26.44 M(+12.1%) |
| Mar 2002 | - | $26.97 M(-321.1%) | $23.59 M(+745.1%) |
| Dec 2001 | $2.79 M(-105.7%) | -$12.20 M(-278.4%) | $2.79 M(-83.3%) |
| Sept 2001 | - | $6.84 M(+245.6%) | $16.75 M(-185.2%) |
| June 2001 | - | $1.98 M(-68.0%) | -$19.67 M(-49.5%) |
| Mar 2001 | - | $6.17 M(+249.5%) | -$38.95 M(-20.5%) |
| Dec 2000 | -$48.97 M(+716.2%) | $1.77 M(-106.0%) | -$48.97 M(-3.5%) |
| Sept 2000 | - | -$29.59 M(+71.0%) | -$50.74 M(+139.9%) |
| June 2000 | - | -$17.30 M(+349.3%) | -$21.15 M(+449.3%) |
| Mar 2000 | - | -$3.85 M | -$3.85 M |
| Dec 1999 | -$6.00 M | - | - |
FAQ
- What is Sangamo Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Sangamo Therapeutics?
- What is Sangamo Therapeutics annual CFI year-on-year change?
- What is Sangamo Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Sangamo Therapeutics?
- What is Sangamo Therapeutics quarterly CFI year-on-year change?
- What is Sangamo Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Sangamo Therapeutics?
- What is Sangamo Therapeutics TTM CFI year-on-year change?
What is Sangamo Therapeutics annual cash flow from investing activities?
The current annual CFI of SGMO is $153.53 M
What is the all time high annual CFI for Sangamo Therapeutics?
Sangamo Therapeutics all-time high annual cash flow from investing activities is $248.20 M
What is Sangamo Therapeutics annual CFI year-on-year change?
Over the past year, SGMO annual cash flow from investing activities has changed by +$94.25 M (+158.97%)
What is Sangamo Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of SGMO is $233.00 K
What is the all time high quarterly CFI for Sangamo Therapeutics?
Sangamo Therapeutics all-time high quarterly cash flow from investing activities is $89.30 M
What is Sangamo Therapeutics quarterly CFI year-on-year change?
Over the past year, SGMO quarterly cash flow from investing activities has changed by -$37.39 M (-99.38%)
What is Sangamo Therapeutics TTM cash flow from investing activities?
The current TTM CFI of SGMO is $73.91 M
What is the all time high TTM CFI for Sangamo Therapeutics?
Sangamo Therapeutics all-time high TTM cash flow from investing activities is $248.20 M
What is Sangamo Therapeutics TTM CFI year-on-year change?
Over the past year, SGMO TTM cash flow from investing activities has changed by -$84.53 M (-53.35%)